Medios AG Shows Strong Growth in First Half of 2024

Medios AG, a leading provider of Specialty Pharma in Europe, reported significant growth in the first half of 2024. Revenue increased by 6.3% to €907.3 million, while EBITDA pre1 rose by 7.3% to €31.1 million. This was highlighted by a marked improvement in cash flow from operating activities, which reached €34.0 million.

The Pharmaceutical Supply segment saw a 7.3% rise in revenue to €787.9 million and a 15.0% increase in EBITDA pre1 to €22.9 million. However, the Patient-Specific Therapies segment experienced a 9.6% decline in revenue due to regulatory price adjustments and other costs, reducing its EBITDA pre1 by 13.1% to €10.9 million.

In June 2024, Medios completed its acquisition of Ceban Pharmaceuticals, enhancing its presence in the Dutch, Belgian, and Spanish markets. This new International segment reported €11.6 million in revenue and an EBITDA pre1 of €2.7 million.

CEO Matthias Gaertner emphasized that the completion of the Ceban acquisition was a key milestone, supporting Medios' strategy of transformation into a European Specialty Pharma platform. The company remains optimistic and has confirmed its financial outlook for 2024.